The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas
The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas
复制标题
DOI：
10.1007/bf02893360
复制
发表时间：
2006-01-01
影响因子：
2.8
通讯作者：
Torp, Sverre Helge
中科院分区：
文献类型：
--
作者：
Johannessen, Anne Linn;Torp, Sverre Helge
目前世界卫生组织对人类星形细胞瘤的分类在预测预后和诊断方面存在局限性，需要其他因素。一些研究已经调查了这些肿瘤的增殖活性的临床价值，特别是Ki-67/MIB-1标记指数（LI）。本研究的目的是回顾有关这一主题的文献，以了解目前的经验。所有研究均显示Ki-67/MIB-1 LI值随恶性程度的增加而增加。他们中的大多数人表明，MIB-1 LI区分弥漫性星形细胞瘤WHO II级（AII）和间变性星形细胞瘤（AA）之间，AII和胶质母细胞瘤（GM）之间，但AA和GM之间没有。然而，不同恶性肿瘤组之间的指数存在相当大的重叠。此外，在大多数研究中，发现MIB-1 LI和生存率之间存在正相关性，尽管报告之间的建议截止值差异很大。回顾的研究报告MIB-1 LI是人类星形细胞瘤的一个重要预后因素。然而，由于各种肿瘤等级之间的值的巨大传播，MIB-1 LI不能单独用作诊断因素，而应与已建立的组织学恶性标准结合使用。它可能是特别有用的情况下，组织学显示一个低级别的星形细胞瘤，而其他参数表明一个更恶性肿瘤。因此，我们认为MIB-1 LI应该成为星形细胞肿瘤患者常规检查的一部分。在基于标准化免疫组织病理学程序的大型多中心研究完成之前，每个实验室必须建立自己的实践。
The current WHO classification of human astrocytomas has limitations in predicting prognosis and diagnosis, and there is a need for additional factors. Several studies have investigated the clinical value of proliferative activity in these tumors, especially the Ki-67/MIB-1 labeling index (LI). The aim of this study was to review the literature on this topic to get a survey of the current experience. All studies show increasing values of Ki-67/MIB-1 LI with increasing grade of malignancy. Most of them demonstrate that MIB-1 LI differentiates well between diffuse astrocytomas WHO grade II (AII) and anaplastic astrocytomas ( AA) and between AII and glioblastomas ( GM), but not between AA and GM. There is, however, considerable overlap of indices between the different malignancy groups. Further, in most studies positive correlations between MIB-1 LI and survival are found, though the proposed cut-off values vary substantially between the reports. The studies reviewed report MIB-1 LI as an important prognostic factor in human astrocytomas. Due to the great spread of values between the various tumor grades, however, MIB-1 LI cannot be used as a diagnostic factor alone but should be used in combination with established criteria of histological malignancy. It may be especially useful in cases where histology reveals a low-grade astrocytoma whereas other parameters indicate a more malignant neoplasm. Thus, it is our opinion that MIB-1 LI should be a part of the routine investigation in patients with astrocytic tumors. Until larger multicenter studies based on standardized immunohistopathological procedures have been completed, each laboratory has to establish its own practice.